Drug intelligence / Profile preview

HCP-2202

Development stage: Preclinical
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HCP-2202 is a fixed-dose combination drug candidate under development by Hanmi Pharmaceutical for the treatment of unspecified cardiovascular disorders, gastric ulcers, and duodenal ulcers. It consists of two components, RLD2202 and RLD2203. The drug has undergone Phase 1 clinical trials to evaluate its pharmacokinetic characteristics and safety in healthy volunteers under both fasting and fed conditions. As of the latest available data, it remains in preclinical or early clinical development stages for its primary indications[1][2][3][4].

Brand names: Rabpirin
Other names: aspirin + rabeprazole sodium

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on HCP-2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP-2202.

Explore the full profile